[1]

NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.

[2]

ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.

[3]

CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.

[4]

LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.

[5]

XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.

[6]

KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.

[7]

LIU Guijian, CHENG Kuan, ZHU Wenqing, GE Junbo. Progress of hypertension pharmacological treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 446-449.

[8]

CHENG Kuan. New progress in research and application of fenneridone [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 450-456.

[9]

YE Peng, TAN Xing, LENG Yueqi, WANG Yangkai, WANG Weizhong. Current opinions and developments of non-pharmacological treatments of hypertension based on sympathetic nervous system [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1335-1343.

[10]

XIE Xiangmei, HUANG Zhihong, LIU Xiaoju, XUE Bing, LAN Baozhu. Effects of atorvastatin and folic acid tablets on homocysteine and carotid atherosclerosis in patients with type H hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 455-459.

[11]

WANG Jiaxin, YANG Guanlin, PENG Bo. Clinical effect observation of Ping gan zi yin tong yu Fang combined with amlodipine besylate in the treatment of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 205-211.

[12]

WEI Zihan,LI Dongbo，YUAN Zheng,LU Ying, YANG Guojie. Clinical trial of sacubitril/valsartan in the treatment of Pulmonary hypertension (PH) due to left heart disease (LHD) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 57-62.

[13]

HAO Wei, SHEN Yuanyuan, ZHANG Junxiu, YANG Jieren. Effects of sesamin combined with vitamin E on the cardiomyocyte apoptosis of spontaneously hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1221-1227.

[14]

ZHANG Xiaoyu, FANG Zhengmei, YAO Yingshui. Association of leptin and leptin receptor gene polymorphisms with hypertension: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 910-916.

[15]

LIU Yu, ZHANG Ying, WANG Ancai. Effect of rhBNP on chronic systolic heart failure combined with diuretic resistance and concentration of TNF-α and NPY [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 814-820.

PDF (PC)

Knowledge